Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) shot up 0.4% during trading on Tuesday . The company traded as high as $5.16 and last traded at $5.16. 1,502 shares were traded during mid-day trading, a decline of 93% from the average session volume of 20,660 shares. The stock had previously closed at $5.14.
Idorsia Stock Performance
The business’s 50-day simple moving average is $4.90 and its two-hundred day simple moving average is $4.50.
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
